$VNDA

12 Health Care Stocks Moving In Monday's Intraday Session

This article lists 12 healthcare stocks that experienced significant movement during Monday's intraday trading session. It highlights several gainers, including Arcellx (NASDAQ: ACLX) and Vanda Pharmaceuticals (NASDAQ: VNDA), and several decliners such as Gossamer Bio (NASDAQ: GOSS) and 20/20 Biolabs (NASDAQ: AIDX), along with their respective percentage changes and market caps.

Original reporting
Benzinga · Benzinga Insights, Benzinga Staff Writer
Published Feb 23, 2026, 5:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Feb 23, 2026, 5:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
12 Health Care Stocks Moving In Monday's Intraday Session — source image
Decision brief

The 30-second read

$VNDANeutralMed
01

Why it matters

Short-term trading opportunities exist based on intraday momentum; however, fundamental factors are not discussed.

02

Market read

The stocks mentioned are active in the healthcare sector with recent intraday volatility, providing potential trading opportunities for short-term traders.

03

What to watch

Broader market trends, upcoming earnings reports, and sector news could significantly influence stock movements beyond current data.

Relevance 6/10Timing: Immediate; intraday movements suggest short-term trading opportunities.

Background

The article reports on intraday movements of 12 healthcare stocks, highlighting both gainers and decliners.

Company-level read

Ticker impact

$VNDANeutralMedium confidence
Context

Moderate relevance; highlighted as a gainer but with less explicit sentiment data.

Expected impact

Potential slight upward movement of 1-2% if current trend persists.

Evidence & confidence

Limited sentiment data and moderate relevance imply cautious optimism; traders should monitor upcoming news for confirmation.

$GOSSBearishMedium confidence
Context

Low relevance; mentioned as a decliner with no specific sentiment data.

Expected impact

Possible further decline of 2-4% if negative momentum continues.

Evidence & confidence

Recent decline suggests bearish sentiment; risk of continued downward movement exists.

$AIDXBearishLow confidence
Context

Low relevance; minor mention as a decliner without detailed sentiment.

Expected impact

Potential for continued decline, but with low confidence due to limited data.

Evidence & confidence

Insufficient sentiment and technical data; traders should await further confirmation.

Market effects

Healthcare sector showing active trading, possibly indicating sector-wide volatility.

Limited; focus remains on specific stocks without broader regional implications.

Low; news pertains mainly to individual stocks within the US healthcare sector.

Counterpoint

The recent intraday gains may be temporary; overbought conditions could lead to reversals.

Key entities

  • Arcellx

    A biotechnology company focused on cell therapies.

  • Vanda Pharmaceuticals

    A biopharmaceutical company developing treatments for central nervous system disorders.

  • Gossamer Bio

    A biotechnology company developing therapies for various diseases.

  • 20/20 Biolabs

    A biotech firm engaged in developing novel therapeutics.

Related articles

$VNDAHighAI 8/10

Vanda reports positive trial results for GLP-1 vomiting drug

Vanda Pharmaceuticals (VNDA) reported positive Phase III trial results for NEREUS (tradipitant) in preventing vomiting in GLP-1 therapy patients. The study met primary and secondary endpoints, showing significant reductions in vomiting rates compared to placebo. VNDA plans to discuss results with the FDA and seeks approval for this new indication. The drug was well-tolerated with no new safety concerns.

$VNDAMedAI 8/10

Vanda Pharmaceuticals Announces Positive Results from Study 3601 of NEREUS™ (tradipitant) for Prevention of GLP-1-Induced Vomiting

Vanda Pharmaceuticals (VNDA) reported positive Phase III results for NEREUS™ (tradipitant) in preventing vomiting linked to GLP-1 therapies. The study showed significant reductions in vomiting (27% p=0.006), severe nausea (35% p=0.002), and extreme vomiting (81% p=0.0003). Vanda plans to discuss results with the FDA and submit an sNDA for this indication.

$GOSSHighAI 8/10

Chardan reiterates Gossamer Bio stock rating on PAH drug outlook

Chardan reiterated a Buy rating and $160 price target for Gossamer Bio (GOSS) after its healthcare conference. Dr. Roxana Sulica expressed safety concerns about WINREVAIR but supported seralutinib. Management expects FDA NDA acceptance by early December, triggering a $125M financing tranche. GOSS trades at $9.61 with a $58.75M market cap, facing liquidity pressures.

$VNDAHighAI 8/10

Vanda Pharmaceuticals’ VQW-765 misses primary endpoint

Vanda Pharmaceuticals (VNDA) shares dropped 6.2% after hours as its Phase III trial for VQW-765 failed to meet the primary endpoint in treating acute anxiety in adults with social anxiety disorder. The study was a multicenter, randomized, double-blind, placebo-controlled trial conducted at 30 U.S. sites.